

The association between diabetes and mortality among patients hospitalized with COVID-19: Cohort Study of Hospitalized Adults in Ontario, Canada and Copenhagen, Denmark

Orly Bogler, MD^{1,2}, Afsaneh Raissi², Michael Colacci, MD¹, Andrea Beaman BScPhm, PharmD, RPh³, Tor Biering-Sørensen MD, PhD, MPH⁴, Alex Cressman, MD, MSc¹, Allan Detsky, MD, PhD^{1,2}, Alexi Gosset, BA^{1,2}, Mats Højbjerg Lassen, MD⁴, Chris Kandel, MD, PhD⁵, Yaariv Khaykin, MD⁶, David Barbosa⁶, Lauren Lapointe Shaw, MD, PhD⁷, Derek R. MacFadden, MD, ScD⁸, Alexander Pearson, MD⁹, Bruce Perkins, MD, MPH², BSc, Kenneth J. Rothman, DrPH¹¹, Kristoffer Grundtvig Skaarup, MD⁴, Rachael Weagle¹², MD, MPH, Chris Yarnell, MD¹³, Michelle Sholzberg, MDCM, MSc^{1,10}, Bena Hodzic-Santor MD Candidate^{1,2}, Erik Lovblom², Jonathan Zipursky, MD¹, Kieran L. Quinn, MD, PhD^{1,2,14}, and Mike Fralick^{1,2}, MD, SM, PhD

KQ and MF were co-senior authors

Affiliations

1. Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, ON, Canada.
2. Sinai Health System, Department of Medicine, University of Toronto, Toronto, ON, Canada
3. Trillium Health Partners, Mississauga, ON, Canada.
4. Department of Cardiology, University of Copenhagen, Denmark
5. Michael Garron Hospital, Toronto, ON, Canada
6. Department of Medicine, Southlake Regional Health Centre, Newmarket, ON, Canada
7. University Health Network, Toronto, ON, Canada.
8. The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
9. Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
10. St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
11. Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA.
12. Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada.
13. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.
14. Interdepartmental Division of Palliative Care, Sinai Health System and University of Toronto, Toronto, ON, Canada.

Correspondence: Michael Fralick, MD, PhD, SM, FRCPC
Sinai Health System
60 Murray Street
M5T 3L9
email: mike.fralick@mail.utoronto.ca

words: 2,474 figures: 2 tables: 2

Study concept and design: All authors

Acquisition of data: All authors

Analysis/interpretation of data: All authors

Drafting of the manuscript: Bogler O, Fralick M

Critical revision of the manuscript: All authors

Statistical analysis: All authors

Obtained funding: This research is supported by Sinai Health Department of Medicine Research fund.

Conflicts of interest: None

Abstract (wordcount: 238)

Importance: Diabetes has been reported to be associated with an increased risk of death among patients with COVID-19. However, available studies lack detail on COVID illness severity and measurement of relevant comorbidities.

Design, Setting, and Participants: We conducted a multicenter, retrospective cohort study of patients over the age of 18 years who were hospitalized with COVID-19 between January 1, 2020 and November 30, 2020 in Ontario, Canada and Copenhagen, Denmark. Chart abstraction emphasizing co-morbidities and disease severity was performed by trained research personnel. The association between diabetes and death was measured using Poisson regression.

Main Outcomes and Measures: within hospital 30-day risk of death.

Results: Our study included 1018 hospitalized patients with COVID-19 in Ontario and 305 in Denmark, of whom 405 and 75 patients respectively had pre-existing diabetes. In both Ontario and Denmark, patients with diabetes were more likely to be older, have chronic kidney disease, cardiovascular disease, higher troponin levels, and to receive antibiotics compared with adults who did not have diabetes. In Ontario, the crude mortality rate ratio among patients with diabetes was 1.60 [1.24 – 2.07 95% CI] and in the adjusted regression model was 1.19 [0.86 – 1.66 95% CI]. In Denmark, the crude mortality rate ratio among patients with diabetes was 1.27 (0.68 – 2.36 95% CI) and in the adjusted model was 0.87 (0.49 – 1.54 95% CI). Meta-analyzing the two rate ratios from each region resulted in a crude mortality rate ratio of 1.55 (95% CI 1.22,1.96) and an adjusted mortality rate ratio of 1.11 (95% CI 0.84, 1.47).

Conclusions: Presence of diabetes was not strongly associated with in-hospital COVID mortality independent of illness severity and other comorbidities.

INTRODUCTION

Since January 2020, over 450 million people worldwide have been infected with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and more than 5 million people have died. Reported risk factors for contracting Coronavirus Disease 2019 (COVID-19) include male sex, older age, living in congregate settings such as a long-term care facility or shelter, or having social, economic, or personal barriers that limit healthcare access (1, 2). Reported risk factors associated with experiencing a more severe course of COVID-19 include older age, male sex, diabetes mellitus, hypertension, obesity, cardiac disease, and chronic kidney disease (3-5).

Much attention has focused on diabetes and COVID-19 given its reported association with a worse prognosis, including an increased risk of intensive care unit (ICU) admission (3, 6-9), mechanical ventilation (3, 10), and mortality (4, 11-14). Within these studies, there is considerable variability in the measured strength of the association between diabetes and adverse clinical outcomes. Uncertainty remains about whether diabetes itself increases the risk of adverse outcomes given its inherent pro-inflammatory state, or whether the association is a result of related comorbid conditions (given that diabetes is an independent predictor of microvascular and macrovascular disease) or differences in care processes (15-17). From a patient perspective, it is not known if someone with diabetes, but without complications or comorbidities, carries a comparable risk of severe clinical outcomes from COVID-19 as a person with diabetes and late-stage complications such as advanced kidney or cardiovascular disease.

Existing studies describing the relationship between diabetes and COVID-19 severity have typically included single center or regional data and patients with varying illness severity.

The main objective of our study was to understand the association between diabetes and death among patients hospitalized with COVID-19.

METHODS

Study Setting and Data Source

We conducted a retrospective (Ontario) and prospective (Denmark) cohort study at 10 hospitals in Ontario, Canada and 8 in Copenhagen, Denmark. The sites represented a convenience sample of hospitals where the study team members worked. The electronic medical record was the primary source of data collection and manual data collection was performed by trained research personnel. Our study was approved by the institutional research ethics board at each participating institution. For data privacy reasons we were unable to combine the data from Ontario and Denmark into one single dataset and thus we report results separately.

Study population

The cohort included adults 18 years or older hospitalized with COVID-19 between January 1, 2020, and November 30, 2020. Consecutive patients hospitalized with COVID-19 were identified using Infection Prevention and Control departments at each hospital and through access to a central repository where SARS-CoV-2 laboratory results were reported. Patients were classified as having diabetes mellitus by one of the following at hospital presentation: hemoglobin A1C $\geq 6.5\%$, current use of at least one oral or injectable diabetes medication, or chart review with a physician's note indicating the patient had diabetes. We were not able to distinguish between type 1 and type 2 diabetes or classify diabetes by severity.

Data Collection

Information abstracted included patient demographics (age, sex, English proficiency, and place of residence before the hospitalization: home, homeless, long-term care, transfer from another hospital), pre-existing medical conditions previously shown to be associated with mortality from COVID-19 (cardiovascular disease, pulmonary disease, smoking, renal failure) (18), in-hospital laboratory results (completed blood count, markers previously shown to be associated with severity of illness at presentation such as D-dimer, C-reactive protein [CRP], troponin), imaging tests (using the first available of chest x-ray [CXR], CT chest, echocardiogram, and doppler ultrasound), medications, and clinical outcomes. Our proxies for disease severity included markers known to be associated with worse clinical outcomes: CRP, troponin, creatinine, D-dimer, abnormal CXR, and need for supplemental oxygen (19). Text mapping using natural language processing was used to characterize the findings on each imaging report.

Patient Follow-up

Measurements began on the date of hospitalization for COVID-19 (the index date) and follow-up continued until death, discharge from hospital, or 30 days from the index date. This specification of the follow-up period was the same as that used in the in-hospital COVID-19 clinical trials (20-22). Our primary outcome was within hospital 30-day risk of death.

Data analysis

Descriptive statistics were used to compare baseline characteristics between the two groups. The association between diabetes and death was measured using Poisson regression that include patient level characteristics including age, sex, admission location, comorbid conditions (heart failure, cerebrovascular disease [CVD], hypertension [HTN], COPD/asthma, smoking, and kidney disease, and proxies for illness severity (CRP, troponin, creatinine, D-dimer, and need for supplemental oxygen). A separate Poisson regression model was performed in the Ontario and Danish data and the results were meta-analyzed to provide an overall rate ratio for mortality

Results

Our study included 1,438 hospitalized patients with COVID-19, including 1,133 (78.8%) from Ontario and 305 (21.2%) from Denmark. 480 patients (33.4%) had diabetes, 405 from Ontario and 75 from Denmark. In Ontario, people with diabetes were older and had more comorbidities (e.g., chronic kidney disease, cardiovascular disease, heart failure and hypertension) than those who did not have diabetes (Table 1a). They were also more likely to be from a long-term care home and have higher severity of illness at presentation to hospital (e.g., higher CRP and D-dimer, abnormal chest x-ray) (Table 2a). They also had higher troponin and creatinine values compared with patients without diabetes. In Denmark, patients with diabetes also were older and had more comorbidities than those without diabetes (Table 1b). They had a higher creatinine and troponin at time of presentation as well. In Denmark, CRP and D-dimer levels were similar between those with diabetes and those without, and both groups were equally likely to have an abnormal CXR (Table 2b).

In both Ontario and Denmark, people with diabetes were more likely to receive an antibiotic and less likely to receive an anti-viral medication (Tables 3a and 3b). In Ontario, steroid use was uncommon and occurred at a similar frequency for the two groups. There was also no clear difference in the number of patients with and without diabetes who received a CT thorax, echocardiogram, or doppler ultrasound of the lower extremities (Table 3a). In Denmark, all patients received an echocardiogram, none received a biologic, and data on doppler studies and steroid administration was not collected (Table 3b).

In Ontario, the crude mortality ratio for patients with diabetes, compared with non-diabetic, was 1.60 (95% CI 1.24 – 2.07). After adjustment for patient-level characteristics (Table 4), the mortality ratio was 1.19 [95% CI 0.86 – 1.66]. In the Danish patient population, the crude mortality ratio was 1.27 (95% CI 0.68 – 2.36), but after control of confounders the adjusted mortality ratio was 0.87 [95% CI 0.49 – 1.54] (Table 4). Meta-analyzing the two rate ratios from each region resulted in a crude mortality rate ratio of 1.55 (95% CI 1.22,1.96) and an adjusted mortality rate ratio of 1.11 (95% CI 0.84, 1.47).

Discussion

After control of confounding, diabetes was only weakly associated with within hospital 30-day risk of death, with no consistent pattern in Canada and Denmark. Multiple studies assessing whether diabetes was associated with an increased risk of mortality lacked information on severity of illness on presentation (e.g., chest x-ray findings) or lab values associated with a worse prognosis (e.g., troponin, d-dimer, creatinine). The strongest predictor of respiratory failure and mortality among COVID patients, aside from age, is illness severity at presentation

(19). Studies that fail to account for these important confounders may overestimate the independent effect of diabetes on COVID outcomes.

Patients with diabetes tended to have both more severe illness (e.g., higher CRP, worse chest x-ray findings) and worse prognostic signs in both countries that we studied. It is unknown if patients with diabetes are sicker on presentation because of delays in seeking care causing selection bias, association between diabetes and other factors that may influence severity such as race or socioeconomic deprivation, or the direct influence of diabetes. The higher illness severity may explain why patients with diabetes were more likely to receive antibiotics while in hospital, though subsequent trials have identified that antibiotics are ineffective against COVID-19 (20). The higher use of antibiotics in patients with diabetes may also be explained by their inherent immune-compromised state and their susceptibility to bacterial co-infection.

Our study has important limitations. First, not all patients had a hemoglobin A1C measured and thus only a subset of patients have these data available. As a result, we were not able to identify severity of diabetes for some of the included patients. Second, we did not capture the proportion of patients with type 1 diabetes versus type 2 diabetes; we estimate that approximately 90% of patients had type 2 diabetes based on other published literature (25). Third, we lacked data on other important comorbid conditions such as elevated BMI. A prior meta-analysis identified that the relative risk of mortality was 3.52 in those with BMI \geq 25 and thus an important risk factor for COVID-19 outcomes (26). Residual confounding related to BMI would mean that we overestimated the relationship between diabetes and mortality, which was already weak after adjustment for confounders. Fifth, this study was conducted in two high-income countries (Denmark and Canada) with socialized healthcare systems; the results may thus not be generalizable to areas of low-income and/or private-paying systems. Unfortunately, our

dataset lacked important social determinants of health such as income, race or ethnicity and education level. Sixth, our study was relatively small. Nonetheless, our finding that diabetes itself may not be a strong risk factor for death within 30 days of hospitalization warrants corroboration from other patient populations.

Table 1a. Baseline characteristics of included patient population (Ontario)

Variable	Strata	Diabetes (n=405)	No Diabetes (n=728)
Age (Mean, SD)	Age (Mean SD)	69.9 (14.0)	62.8 (19.8)
Age group (n, %)	<50 years	32 (7.9)	190 (26.0)
	50-59 years	54 (13.3)	114 (15.7)
	60-69 years	98 (24.2)	124 (17.0)
	70-79 years	112 (27.7)	124 (17.0)
	80-89 years	82 (20.2)	117 (16.1)
	90+ Years	27 (6.7)	59 (8.1)
COVID Positivity Date	On/Before April 25th, 2020	243 (60)	421 (57.8)
	After April 25 th , 2020	162 (40)	307 (42.2)
Nosocomial COVID (%)		55 (13.6)	86 (11.8)
Sex (n, %)	Female	171 (42.2)	308 (42.3)
Limited English Proficiency (%)		50 (12.3)	76 (10.4)
Admission Location (n, %)	Home	252 (62.2)	460 (63.2)
	LTC	91 (22.5)	120 (16.5)
	Hospital (Transfer)	49 (12.1)	79 (10.9)
	No fixed home address	13 (3.2)	69 (9.5)
Comorbidities (n, %)	Hypertension	316 (78.0)	326 (44.8)
	Heart Failure	85 (20.9)	76 (10.4)
	Smoking	97 (23.9)	148 (20.3)
	Cardiovascular Dx	130 (32.1)	135 (18.5)
	COPD	85 (20.9)	122 (16.8)
	CKD	112 (27.7)	59 (8.1)
Creatinine Group, $\mu\text{mol/L}$ (%)	0-100	153 (37.8)	466 (64.0)
	101-200	138 (34.1)	142 (19.5)
	>200	78 (19.3)	37 (5.1)
	Missing	36 (8.9)	83 (11.4)
A1C, % (Mean, SD)		7.844 (2.3)	5.618 (0.4)
	NA (%)	243 (60.0)	663 (91.1)
Lymphocyte, 10^9 cells/L (Mean, SD)		1.133 (0.8)	1.196 (0.8)
	NA (%)	43 (10.6)	80 (10.9)
Ferritin, $\mu\text{g/L}$ (Mean, SD)		937.932 (1443.5)	972 (2096.2)
	NA (%)	198 (48.9)	313 (42.9)

Presence of CXR (%)		345 (85.2)	597 (82.0)
----------------------------	--	------------	------------

SD = standard deviation; LTC = long term care; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; WBC = white blood cell; CXR = chest x-ray

Table 1b. Baseline characteristics of included patient population (Denmark).

Variable	Strata	Diabetes (n=75)	No Diabetes (n=230)
Age (Mean, SD)	Age (Mean SD)	70.3 (13.0)	68.1 (13.9)
Age group (n, %)	50-59	16 (21.3)	67 (29.1)
	60-69	16 (21.3)	51 (22.2)
	70-79	23 (30.7)	52 (22.6)
	80-89	17 (22.7)	49 (21.3)
	90+	3 (4.0)	11 (4.8)
COVID Positivity Date	On/Before April 25th, 2020	47 (62.7)	139 (60.4)
	After April 25 th , 2020	28 (37.3)	91 (39.6)
Nosocomial COVID (%)		14 (18.7)	36 (15.7)
Sex (n, %)	Female	29 (38.7)	102 (44.3)
Admission Location (n, %)	Home	61 (81.3)	194 (84.3)
	LTC/Hospital	14 (18.7)	36 (15.7)
Comorbidities (n, %)	Hypertension	47 (62.7)	126 (54.8)
	Heart Failure	10 (13.3)	24 (10.4)
	Smoking	43 (57.3)	127 (55.2)
	Cerebrovascular Dx	14 (18.7)	37 (16.1)
	COPD	13 (17.6)	33 (14.3)
	CKD	17 (22.7)	29 (12.6)
Creatinine Group, μmol/L (%)	0-100	46 (61.3)	179 (77.8)
	101-200	21 (28.0)	32 (13.9)
	>200	8 (10.7)	16 (7.0)
A1C, mmol/mol (Mean, SD)		55.1 (19.8)	40.9 (6.1)
Lymphocyte, 10^9 cells/L (Mean, SD)		1.6 (1.7)	1.2 (1.0)
Ferritin, μg/L (Mean, SD)		936.7 (1216.7)	947.3 (1064.2)
Presence of CXR (%)		71 (94.7)	218 (94.8)

SD = standard deviation; LTC = long term care; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; WBC = white blood cell; CXR = chest x-ray

Table 2a. Markers of Illness Severity (Ontario)

Variable	Strata	Diabetes (n=405)	No Diabetes (n=728)
CRP Group, mg/L (%)	0-14.9	23 (5.7)	75 (10.3)
	15-100	105 (25.9)	167 (22.9)
	>100	90 (22.2)	138 (18.9)
	Missing	187 (46.2)	348 (47.8)
Median CRP (IQR)		79.3 (37.2 – 151.1)	65.5 (20 – 135.3)
D-Dimer Group	<ULN	26 (6.4)	74 (10.2)
	ULN-2*ULN	61 (15.1)	111 (15.2)
	>2*ULN	137 (33.8)	199 (27.3)
	Missing	181 (44.7)	344 (47.3)
Troponin Group	<ULN	151 (37.3)	294 (40.4)
	ULN-2*ULN	66 (16.3)	89 (12.2)
	>2*ULN	84 (20.7)	99 (13.6)
	Missing	104 (25.7)	246 (33.8)
Oxygen requirement (%)		57 (14.1)	98 (13.5)
	NA (%)	303 (74.8)	537 (73.7)
Presence of ABG		72 (17.8)	102 (14.0)
CXR Results	Normal CXR (%)	59 (14.6)	137 (18.8)
	Abnormal CXR (%)	227 (56.1)	371 (50.9)
	Missing CXR (%)	61 (15.1)	134 (18.4)
	Unknown CXR (%)	39 (9.6)	63 (8.7)

CRP = c-reactive protein; IQR = interquartile range; ULN = upper limit of normal; ABG = arterial blood gas; CXR = chest x-ray

Table 2b. Markers of Illness Severity (Denmark)

Variable	Strata	Diabetes	No Diabetes
CRP Group, mg/L (%)	0-14.9	13 (17.3)	41 (17.8)
	15-100	44 (58.7)	135 (58.7)
	>100	16 (21.3)	47 (20.4)
	Missing	2 (2.7)	7 (3.0)
Median CRP, mg/L (IQR)		48 (23, 89)	56 (23, 96)
D-Dimer Group	<ULN	6 (8.0)	34 (14.8)
	ULN-2*ULN	21 (28.0)	48 (20.9)
	>2*ULN	22 (29.3)	69 (30.0)
	Missing	26 (34.7)	79 (34.3)
Troponin Group	<ULN	24 (32.0)	72 (31.3)
	ULN-2*ULN	7 (9.3)	35 (15.2)
	>2*ULN	18 (24.0)	30 (13.0)
	Missing	26 (34.7)	93 (40.4)
Oxygen requirement (%)		41 (54.7)	124 (53.9)
Presence of ABG		57 (76.0)	154 (67.0)
CXR Results	Normal CXR (%)	1 (1.3)	1 (0.4)
	Abnormal CXR (%)	17 (22.7)	49 (21.3)
	Missing CXR (%)	57 (76.0)	180 (78.3)

CRP = c-reactive protein; IQR = interquartile range; ULN = upper limit of normal; ABG = arterial blood gas; CXR = chest x-ray

Table 3a. Patterns of care in hospital (Ontario).

Variable	Diabetes	No Diabetes
CT Thorax (%)	97 (23.9)	155 (21.3)
Echocardiogram (%)	43 (10.6)	59 (8.1)
Doppler ultrasound (%)	47 (11.6)	68 (9.3)
Antibiotic received (%)	304 (75.1)	492 (67.6)
Antiviral received (%)	52 (12.8)	114 (15.7)
Steroid received (%)	92 (22.7)	145 (19.9)
Biologic received (%)	3 (0.7)	9 (1.2)

Table 3b. Patterns of care in hospital (Denmark)

Variable	Diabetes	No Diabetes
CT Thorax (%)	14 (18.7)	50 (21.8)
Echocardiogram (%)	75 (100.0)	230 (100.0)
Antibiotic received (%)	63 (84.0)	166 (72.2)
Antiviral received (%)	12 (16.0)	45 (19.6)
Biologic received (%) - none	0 (0)	0 (0)

Table 4a. Univariate and multivariable model for the association between diabetes and death (Ontario).

Variable	Univariate		Multivariable	
	MR	95% CI	MR	95% CI
Diabetes	1.60	1.24 – 2.07	1.19	0.86 – 1.66
Age (ref < 60 years)				
60-69	3.30	1.78 – 6.15	2.24	1.12 – 4.51
70-79	4.64	2.6 – 8.26	2.90	1.45 – 5.78
80-89	7.39	4.25 – 12.85	4.46	2.27 – 8.75
90+	11.89	6.83 – 20.69	5.96	2.78 – 12.79
Sex (Male)	1.09	0.84 – 1.41	1.17	0.86 – 1.59
Admission Location (Ref Home)				
Shelter	0.15	0.04 – 0.6	0.47	0.14 – 1.65
LTC	2.06	1.6 – 2.66	1.13	0.8 – 1.59
Heart failure	1.81	1.36 – 2.4	0.97	0.65 – 1.43
CVD	2.12	1.64 – 2.74	1.28	0.92 – 1.77
Smoking	0.96	0.68 – 1.36	0.91	0.63 – 1.3
COPD/Asthma	0.97	0.69 – 1.36	0.86	0.6 – 1.24
HTN	2.37	1.72 – 3.25	1.10	0.75 – 1.62
Creatinine (µmol/L) (Ref 0-100)				
- 101-200	2.36	1.76 – 3.17	1.43	0.99 – 2.06
- >200	2.99	2.14 – 4.19	1.53	0.91 – 2.55
- Missing	1.11	0.43 – 2.84	1.37	0.4 – 4.73
CRP (Ref 0-14.9)				
- >100	6.16	2.56 – 14.82	3.73	1.21 – 11.48
- 15-100	3.20	1.31 – 7.85	2.65	0.86 – 8.2
- Missing	3.32	1.38 – 8	2.77	0.91 – 8.4
Troponin (Ref <ULN)				
- ULN-2*ULN	1.84	1.28 – 2.65	1.00	0.64 – 1.55
- >2*ULN	2.92	2.16 – 3.94	1.53	0.98 – 2.41
- Missing	0.70	0.45 – 1.09	0.71	0.42 – 1.2
CXR results (Ref Normal or Unknown)				
- Abnormal	1.59	1.15 – 2.2	1.28	0.88 – 1.87
- Missing	0.97	0.61 – 1.55	1.22	0.73 – 2.04

MR = mortality ratio; CI = confidence intervals; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; HTN = hypertension; CRP = c-reactive protein; ULN = upper limit of normal; CXR = chest x-ray

Table 4b. Univariate and multivariable model for the association between diabetes and death (Denmark).

Variable	Univariate		Multivariable	
	MR	95% CI	MR	95% CI
Diabetes	1.27	0.68 – 2.36	0.87	0.49 – 1.54
Age (Ref <60)				
60-69	5.00	0.57 – 43.45	4.45	0.54 – 36.89
70-79	15.5	2.07 – 115.39	14.71	2.11 – 102.34
80-89	21.4	2.91 – 157.02	14.98	2.18 – 103.02
90+	29.6	3.72 – 235.95	17.75	2.28 – 138.06
Sex (Male)	2.05	1.07 – 3.95	1.34	0.68 – 2.63
Admission Location (Ref Home)				
LTC	1.87	1 – 3.48	1.92	1.02 – 3.59
Heart failure	2.57	1.39 – 4.77	0.64	0.33 – 1.25
CVD	2.58	1.46 – 4.58	1.89	0.94 – 3.79
Smoking	1.12	0.63 – 2	0.68	0.32 – 1.47
COPD/Asthma	0.86	0.44 – 1.68	1.07	0.48 – 2.36
HTN	1.84	0.98 – 3.48	0.66	0.3 – 1.44
Creatinine (µmol/L) (Ref 0-100)				
- 101-200	4.25	2.27 – 7.93	3.96	1.8 – 8.68
- >200	4.69	2.24 -9.81	2.17	0.92 – 5.09
- Missing	4.69	0.88 – 24.93	2.55	0.44 – 14.62
CRP (Ref 0-14.9)				
- >100	7.29	1.76 – 30.19	4.93	1.28 – 19
- 15-100	3.17	0.76 – 13.11	2.61	0.71 – 9.59
- Missing	3.00	0.3 – 29.87	1.6	0.22 – 11.71
Troponin (Ref <ULN)				
- ULN-2*ULN	3.81	0.95 – 15.25	1.52	0.39 – 5.95
- >2*ULN	6.00	1.7 – 21.19	1.00	0.28 – 3.62
- Missing	6.45	2 – 20.83	3.88	1.08 – 13.97
CXR results (Ref Normal/Unknown)				
- Abnormal	0.48	0.11 – 2.07	3.15	0.97 – 10.2
- Missing	0.20	0.048 – 0.85	1.13	0.42 – 3.05

MR = mortality ratio; CI = confidence intervals; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; HTN = hypertension; CRP = c-reactive protein; ULN = upper limit of normal; CXR = chest x-ray

References

1. Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. *BMJ Open*. 2021;11(1):e044640.
2. Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US. *JAMA Network Open*. 2021;4(1):e2036462-e.
3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020;382(18):1708-20.
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-42.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395(10229):1054-62.
6. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes Care*. 2020;43(7):1382-91.
7. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *Journal of Clinical Virology*. 2020;127:104354.
8. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology*. 2020;109(5):531-8.
9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *Jama*. 2020;323(20):2052-9.
10. Sun Y, Guan X, Jia L, Xing N, Cheng L, Liu B, et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. *Journal of Clinical Hypertension*. 2021;23(2):218-31.
11. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *The Lancet Diabetes & Endocrinology*. 2020;8(10):813-22.
12. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *The Lancet Diabetes & Endocrinology*. 2020;8(10):823-33.
13. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metabolism*. 2020;31(6):1068-77.e3.
14. Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al. Type 2 Diabetes and COVID-19-Related Mortality in the Critical Care Setting: A National Cohort Study in England, March-July 2020. *Diabetes Care*. 2021;44(1):50-7.

15. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. *The Lancet Diabetes & Endocrinology*. 2020;8(9):782-92.
16. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nature Reviews Endocrinology*. 2021;17(1):11-30.
17. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. *Endocrine Reviews*. 2020;41(3):01.
18. Gao Y-d, Ding M, Dong X, Zhang J-j, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy*. 2021;76(2):428-55.
19. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. *BMJ*. 2020;369:m1996.
20. Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*. 2021;397(10274):605-12.
21. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *New England Journal of Medicine*. 2020;384(6):497-511.
22. Fralick M, Colacci M, Munshi L, Venus K, Fidler L, Hussein H, et al. Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial [COVID-PRONE]. *medRxiv*. 2021:2021.11.05.21264590.
23. Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. *Reviews in Endocrine and Metabolic Disorders*. 2021;22(2):275-96.
24. Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetes and COVID-19: The past, the present, and the future. *Metabolism*. 2021;121:154814.
25. Verma AA, Hora T, Jung HY, Fralick M, Malecki SL, Lapointe-Shaw L, et al. Characteristics and outcomes of hospital admissions for COVID-19 and influenza in the Toronto area. *Canadian Medical Association Journal*. 2021;193(12):E410-E8.
26. Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J, Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis. *Endocrinology, Diabetes & Metabolism*. 2021;4(1):e00176.
27. Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine*. 2020;384(8):693-704.